Table 2. Univariate analyses for comparisons between the modified LANZA score and each independent variable.
| Variable | Coefficient of determination (r^2) | p-value |
|---|---|---|
| Age | 0.00178 | 0.082* |
| Sex | 0.0000122 | 0.886 |
| Steinbrocker stage | 0.000372 | 0.427 |
| Steinbrocker class | 0.00498 | 0.036** |
| Disease duration | 0.000397 | 0.413 |
| PSL dose | 0.00512 | <0.001*** |
| Duration of PSL | 0.000129 | 0.680 |
| Usage of NSAIDs | 0.00875 | <0.001*** |
| Duration of NSAIDs | 0.0000699 | 0.791 |
| PPIs | 0.00194 | 0.070* |
| H2RAs | 0.0000719 | 0.726 |
| Gastroprotective drugs | 0.00228 | 0.049** |
| H. pylori (a) | 0.00331 | 0.410 |
PSL, prednisolone; NSAIDs, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors; H2RAs, histamine H2-receptor antagonists.
(a) A total of 207 cases of 1704 cases were tested.
Data were analyzed using Pearson’s correlation coefficient,
*p<0.1,
**p<0.05,
***p<0.01.